All In Biotech

NDA 211566 · Zydus Lifesciences

Zituvio

Sitagliptin · Oral · Dipeptidyl Peptidase 4 Inhibitor

Last checked: Nov 19, 2026Latest source record: Oct 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 18, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

511

155 Phase 3, 14 recruiting

FAERS reports

10,989

10,521 serious, 1,161 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2026.

ZITUVIO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use ZITUVIO is not recommended in patients with type 1 diabetes mellitus. ZITUVIO has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using ZITUVIO. [see Warnings and Precautions (5.1) ]. ZITUVIO is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: ZITUVIO is not recommended in patients with type 1 diabetes mellitus. ( 1 ) ZITUVIO has not been studied in patients with a history of pancreatitis. ( 1 )

Mechanism: Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZITUVIO · SITAGLIPTIN 100MG · TABLET, ORAL · Prescription
  • ZITUVIO · SITAGLIPTIN 25MG · TABLET, ORAL · Prescription
  • ZITUVIO · SITAGLIPTIN 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sitagliptin" as an intervention, any sponsor and status, largest first.

All 511 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • acute kidney injury913
  • diarrhoea621
  • nausea561
  • general physical health deterioration553
  • fatigue536
  • dyspnoea534
  • vomiting524
  • lactic acidosis495
  • drug interaction446
  • drug ineffective402
  • off label use390
  • anaemia389

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20078
200826
200948
2010195
2011141
2012115
2013191
2014225
2015356
2016432
2017520
2018799
2019801
2020996
2021959
20221,025
2023874
20241,057
20251,201
20261,020

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 742 on PubMed

Sponsor: Zydus Lifesciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.